Bridgeway Capital Management’s Pyxis Oncology PYXS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$251K Buy
107,824
+26,564
+33% +$80.4K ﹤0.01% 964
2026
Q2
$245K Hold
81,260
– – ﹤0.01% 1019
2026
Q1
$119K Buy
81,260
+8,560
+12% +$12.9K ﹤0.01% 1106
2025
Q4
$83.6K Sell
72,700
-4,000
-5% -$14.1K ﹤0.01% 1150
2025
Q3
$170K Sell
76,700
-65,595
-46% -$94.5K ﹤0.01% 1041
2025
Q2
$157K Buy
142,295
+61,500
+76% +$69.3K ﹤0.01% 1010
2025
Q1
$79.2K Sell
80,795
-189,200
-70% -$252K ﹤0.01% 1079
2024
Q4
$421K Buy
269,995
+4,700
+2% +$13.6K 0.01% 851
2024
Q3
$974K Buy
265,295
+18,800
+8% +$65.8K 0.02% 696
2024
Q2
$816K Buy
246,495
+15,000
+6% +$63.1K 0.02% 744
2024
Q1
$986K Sell
231,495
-4,700
-2% -$19.8K 0.02% 748
2023
Q4
$425K Hold
236,195
– – 0.01% 978
2023
Q3
$470K Sell
236,195
-50,000
-17% -$116K 0.01% 895
2023
Q2
$733K Buy
286,195
+115,900
+68% +$368K 0.02% 806
2023
Q1
$683K Hold
170,295
– – 0.02% 810
2022
Q4
$228K Buy
170,295
+50,000
+42% +$75K 0.01% 1059
2022
Q3
$237K Buy
120,295
+50,000
+71% +$131K 0.01% 1102
2022
Q2
$167K Buy
+70,295
New +$187K ﹤0.01% 1128

Other funds holding PYXS

Bridgeway Capital Management's PYXS Position: Q3 2026 in Review

Bridgeway Capital Management increased its Pyxis Oncology (PYXS) stake by 33% in Q3 2026, buying an estimated $80.4K and bringing the position to 107,824 shares worth $251K. The position accounts for ﹤0.01% of the portfolio, ranked #964.

Bridgeway Capital Management first reported a position in PYXS in Q2 2022 and has held it in 18 quarters since. The position peaked at $986K in Q1 2024. 101 funds tracked by Wall St. Rank hold PYXS as of Q3 2026.

  • Bridgeway Capital Management held 107,824 shares of Pyxis Oncology worth $251K as of Q3 2026.
  • Bridgeway Capital Management bought 26,564 Pyxis Oncology shares in Q3 2026, an estimated $80.4K.
  • Pyxis Oncology made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q3 2026, its #964 holding.
  • Bridgeway Capital Management first reported a position in Pyxis Oncology in Q2 2022 and has held it in 18 quarters since.
  • Bridgeway Capital Management's Pyxis Oncology position peaked at $986K in Q1 2024.
  • 101 funds tracked by Wall St. Rank held Pyxis Oncology as of Q3 2026.

Based on Bridgeway Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.